About: Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients
Creator	Hu, Ping Zhang, Libin
source	Medline; PMC
abstract	AIM: Pharmacoeconomic cost-effectiveness analysis of two different dosage regimens of levofloxacin in the treatment of acute lower respiratory tract infection in elderly patients. METHODS: A total of 108 elderly patients with acute lower respiratory tract infection who visited by our hospital between September 2013 and September 2014 were randomly divided into Group A and Group B, with 54 patients in each group. In Group A, levofloxacin injection was given for continuous intravenous infusion treatment, whereas in Group B, levofloxacin injection and levofloxacin capsule were given as sequential therapy (ST). The period of treatment for both the groups was 10 days, and minimum cost analysis was used to analyze the treatment. RESULTS: Groups A and B had cure rates of 61.1% and 59.3% (P>0.05), effective rates of 88.9% and 83.3% (P>0.05), bacterial clearance rates of 96.3% and 92.6% (P>0.05), and incidence rates of adverse reactions of 7.4% and 3.7% (P>0.05), respectively. Treatment costs of Groups A and B were 1,588 RMB and 1,150 RMB, respectively, whereas the cost-effectiveness of the two groups was at 17.86 and 13.81, respectively (P<0.05). CONCLUSION: Levofloxacin ST had relatively higher cost-effectiveness ratio for the treatment of acute lower respiratory tract infection in elderly patients, especially Chinese.
has issue date	2017-04-12(xsd:dateTime)
bibo:doi	10.2147/cia.s127009
bibo:pmid	28442897
has license	cc-by-nc
sha1sum (hex)	13e343269547d19b3be05976232fd5cd627e1d80
schema:url	https://doi.org/10.2147/cia.s127009
resource representing a document's title	Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients
has PubMed Central identifier	PMC5396833
has PubMed identifier	28442897
schema:publication	Clin Interv Aging
resource representing a document's body	covid:13e343269547d19b3be05976232fd5cd627e1d80#body_text
is schema:about of	named entity '2014' named entity 'September' named entity 'Group A' named entity 'dosage' named entity 'groups' named entity 'Aim' covid:arg/13e343269547d19b3be05976232fd5cd627e1d80 named entity 'acute' named entity 'levofloxacin' named entity 'Treatment' named entity 'group' named entity 'clearance' named entity 'continuous' named entity 'bacterial' named entity 'cost-effectiveness' named entity 'cost-effectiveness ratio' named entity 'cost-effectiveness' named entity 'cost-effectiveness analysis' named entity 'lower respiratory tract infection' named entity 'Clinical Interventions in Aging' named entity 'adenoviruses' named entity 'bacterial strain' named entity 'cough reflex' named entity 'dizziness' named entity 'epigastric' named entity 'phototoxicity' named entity 'combination therapy' named entity 'infectious disease' named entity 'ALRI' named entity 'hematuria' named entity 'culture and sensitivity' named entity 'central nervous' named entity 'adverse reactions' named entity 'clearance rate' named entity 'cure rate' named entity 'significant difference' named entity 'bacteria' named entity 'levofloxacin' named entity 'cure rate' named entity 'clearance rate' named entity 'Serratia' named entity 'intravenous administration' named entity 'intravenous infusion' named entity 'infection' named entity 'bacterial infection' named entity 'ALRI' named entity 'bacterial infection' named entity 'type 1' named entity 'China' named entity 'insomnia' named entity 'adverse reactions' named entity 'capsules' named entity 'mental factors' named entity 'sitafloxacin' named entity 'lower respiratory tract infection' named entity 'Streptococcus pneumoniae' named entity 'clinical trials' named entity 'cephalosporins' named entity 'pathogen' named entity 'indirect costs' named entity 'RMB' named entity 'intravenous infusion' named entity 'statistically significant' named entity 'incidence rate' named entity 'human parainfluenza viruses' named entity 'levofloxacin' named entity 'adverse reactions' named entity 'bacteria' named entity 'liver' named entity 'liver' named entity 'intravenous infusion' named entity 'ALRI' named entity 'ofloxacin' named entity 'GBD' named entity 'nausea' named entity 'cost-benefit analysis' named entity 'informed consent' named entity 'climatic' named entity 'clearance rate' named entity 'kidney'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software